Celgene enforces its REVLIMID® patents against Lotus Pharmaceutical under Hatch-Waxman Act
Client(s) Celgene Corporation
Jones Day is representing Celgene Corporation as a plaintiff to enforce its patents against Lotus Pharmaceutical Co., Ltd. in Hatch-Waxman litigations involving proposed generic versions of REVLIMID®, which is prescribed for treating multiple myeloma and other cancers.
Celgene Corporation v. Lotus Pharmaceutical Co., Ltd., et al., Nos. 2-17-cv-06842, 2-18-cv-11518 (D.N.J.)